Ankle cartilage repair therapy trial halted early

NCT ID NCT02537067

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a treatment called Chondron, made from a patient's own cartilage cells, for repairing ankle cartilage defects. The trial aimed to see if the treatment could improve cartilage quality and ankle function over 18 months. However, the study was terminated early and included only 28 people, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Chondron (autologous cultured chondrocytes)

What this could lead to

If successful, this could provide a way to repair ankle cartilage damage, potentially reducing pain and improving joint function.

What could go wrong

The trial was terminated early with only 28 participants, so results are limited. Cartilage repair may not last or may require additional surgeries.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEFECT OF ARTICULAR CARTILAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

articular cartilage disorder joint laxity, familial osteoarthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eulji General Hospital

    Seoul, Seoul, South Korea

  • Myongji Hospital

    Goyang-si, Gyeonggi-do, South Korea